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Abstract
Background—It has been suggested that smokeless tobacco users have high levels of exposure 
to nicotine and some toxic substances as measured by biomarker concentrations, but studies with 
nationally representative data have been limited.
Methods—We analyzed biomarkers of tobacco exposure for 23,684 adult participants from the 
National Health and Nutrition and Examination Survey (NHANES) from 1999-2012. The 
biomarkers analyzed were serum cotinine, urinary 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol 
(NNAL), blood lead, blood cadmium, blood mercury, urinary arsenic, and urinary N-acetyl-S-(2-
cyanoethyl)-L-cysteine (CYMA). We calculated geometric mean concentrations for each 
biomarker by tobacco use category (exclusive smokeless tobacco use, exclusive cigarette smoking, 
dual cigarette and smokeless tobacco use, and non-cigarette and smokeless tobacco use) and 
geometric mean ratios adjusting for demographic factors.
Results—Exclusive smokeless tobacco users had higher geometric mean concentrations of 
cotinine (178.9 ng/mL, 95% CI = 145.5, 220.0) and NNAL (583.0 pg/mg creatinine, 95% CI = 
445.2, 763.5) than exclusive cigarette smokers, (130.6 ng/mL, 95% CI = 122.3, 139.6 and 217.6 
pg/mg creatinine, 95% CI = 193.0, 245.2, respectively). Smokeless tobacco users also had higher 
concentrations of blood lead compared with non-tobacco users (adjusted geometric mean ratio = 
1.30, 95% CI = 1.21, 1.38). Differences in concentrations of cadmium, mercury, and CYMA 
between smokeless tobacco users and non-tobacco users were not observed. Based on limited 
sample sizes, NNAL concentrations for smokeless tobacco users appear to have declined from 
2007-2008 (geometric mean = 1013.7 pg/mg creatinine, 95% CI = 738.9, 1390.8) to 2011-2012 
(geometric mean = 325.7 pg/mg creatinine, 95% CI = 159.6, 664.9).
Corresponding Author: Brian Rostron, Ph.D., Office of Science, Center for Tobacco Products, Food and Drug Administration, 
Document Control Center, Building 71, Room G335, 10903 New Hampshire Avenue, Silver Spring, MD 20993-0002, Phone: (301) 
796-9360, Fax: (240) 276-3655, brian.rostron@fda.hhs.gov. 
Conflict of interest statement: The authors have no conflicts of interest to report.
Disclaimer: The views and opinions expressed in this article are those of the authors only and do not necessarily represent the views, 
official policy or position of the US Department of Health and Human Services or any of its affiliated institutions or agencies.
HHS Public Access
Author manuscript
Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2016 December 
02.
Published in final edited form as:














Conclusions—Smokeless tobacco users have higher observed levels of exposure to nicotine and 
carcinogenic tobacco-specific nitrosamines, as measured by cotinine and NNAL biomarker 
concentrations, than cigarette smokers.
Impact—High levels of exposure to known harmful constituents for smokeless tobacco users is a 
cause of concern for individual and public health.
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Introduction
Use of smokeless tobacco products is attracting increasing attention from the public health 
community. According to the US National Adult Tobacco Survey (NATS), 7.1% of US adult 
males were current users of chewing tobacco, snuff, dip, snus, or dissolvable tobacco 
products in 2012-2013, making smokeless tobacco the most commonly used tobacco 
product among US adults after cigarettes and cigars (1). Smokeless tobacco use is 
particularly common among young people. Among US high school students, 9.6% of males 
were current users of chewing tobacco, snuff, or dip and 2.7% were current users of snus in 
2013 (2) according to the National Youth Tobacco Survey (NYTS) (3), again making 
smokeless tobacco the third most commonly used tobacco product among this group after 
cigarettes and cigars. Smokeless tobacco use prevalence among US youth has also remained 
relatively consistent over time since 2000 according to NYTS data (4), even as cigarette 
smoking prevalence continued to decline among US youth during this period (5).
Biomarkers of tobacco exposure have previously been analyzed for cigarette smokers (6-8) 
and, to some extent, for cigar smokers (9), but less is known about biomarker levels among 
smokeless tobacco users. It is known that tobacco-specific nitrosamine (TSNA) levels in 
smokeless tobacco products themselves can vary due to a variety of factors including 
tobacco type, growing conditions, curing and fermentation processes, and storage conditions 
(10, 11) and that TSNA levels in smokeless tobacco products can vary widely (12-14). It has 
also been suggested that levels of some biomarkers can be as high or higher among 
smokeless tobacco users as among cigarette smokers. For example, Hecht et al. (15) 
analyzed the urinary cotinine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) 
concentrations of 182 smokeless tobacco users and 420 smokers from six studies in the Twin 
Cities, Minnesota and Washington, DC metropolitan areas. The urine samples were collected 
at baseline as part of studies that were designed to reduce participants’ use of these tobacco 
products. Hecht et al. found that smokeless tobacco users had significantly higher 
concentrations of cotinine and NNAL compared with cigarette smokers. Hecht et al. (16) 
subsequently found, using data from the three studies of smokeless tobacco users in the 
Twin Cities area, that cotinine and NNAL concentrations were significantly associated with 
years of smokeless tobacco use. Naufal et al. (17), on the other hand, analyzed biomarkers of 
volatile organic compounds, halogenated aromatic hydrocarbons, polycyclic aromatic 
hydrocarbons, acrylamide, NNAL, and metals from 368 smokeless tobacco users, 5,040 
cigarette smokers, and 16,443 nonconsumers of tobacco and nicotine replacement therapy 
products from US National Health and Nutrition Examination Survey (NHANES) 
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participants from 1999-2008. The authors concluded that biomarker concentrations were 
generally significantly lower among smokeless tobacco users compared with smokers, with 
the exception of NNAL and some halogenated aromatic hydrocarbons. They also did not 
find significant differences between smokeless tobacco users and nonusers with the 
exception of NNAL and some polyaromatic hydrocarbons. More recently, Agaku and King 
(18) used 2003-2010 NHANES data to assess the relationship between self-reported 
smokeless tobacco use and serum cotinine concentrations and identify the optimal cutpoint 
for identifying smokeless tobacco users based on cotinine concentrations. Agaku, Vardavas, 
and Connolly (19) conducted a similar analysis for NNAL using 2007-2010 data. These 
authors did not, however, compare cotinine concentrations for smokeless tobacco users with 
cigarette smokers or users of other tobacco products.
In this study, we analyzed biomarkers of tobacco exposure in a large nationally 
representative sample of US tobacco users and nonusers from the National Health and 
Nutrition Examination Survey (NHANES) from 1999 to 2012. We selected seven 
biomarkers for analysis based on their particular relevance to tobacco exposure and health 
outcomes: cotinine, NNAL, cadmium, lead, mercury, arsenic, and CYMA (N-Acetyl-S-(2-
cyanoethyl)-L-cysteine). We estimated geometric mean biomarker concentrations for 
smokeless tobacco users, cigarette smokers, dual cigarette and smokeless tobacco users, and 
non-tobacco users. We also calculated geometric mean ratios using regression analysis to 
analyze the association between biomarker concentrations and tobacco use status, with and 
without adjustment for demographic and socioeconomic factors such as sex, age, race/
ethnicity, and educational attainment.
Our study builds upon previous research in presenting estimates from a large and nationally 
representative study population for smokeless tobacco users for cotinine, which was not 
included in the previous analysis by Naufal et al., and NNAL, which was only available at 
the time of this previous study for 2007-2008 NHANES participants, as well as the other 
selected biomarkers. As such, we present estimates not only of biomarker concentrations by 
tobacco use status, but also of biomarker concentrations over time, thus allowing us to 
investigate whether differences in product characteristics or product use patterns have 
contributed to changes in biomarker exposure for tobacco users in recent years.
Materials and Methods
Study Population and Tobacco Use Status
We analyzed biomarker concentrations by tobacco use for adult NHANES participants from 
1999-2012. NHANES is a health and examination survey that uses a complex multistage 
design to obtain a nationally representative sample of the US civilian non-institutionalized 
population (20). NHANES has been conducted on a continuous basis by the National Center 
for Health Statistics (NCHS) since 1999 and surveys approximately 10,000 participants of 
all ages in each two-year cycle. Survey participants complete health interviews in their 
homes that include a cigarette smoking history questionnaire for adults aged 20 years and 
older. Participants then complete an additional questionnaire on recent tobacco use including 
smokeless tobacco in a Mobile Examination Center (MEC), where they also receive a 
medical examination that includes the collection of biospecimens such as urine and blood.
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We analyzed biomarker concentrations among the 38,024 adults aged 20 years and older 
who participated in NHANES between 1999 and 2012. We excluded 736 survey participants 
who reported use of tobacco or nicotine products other than cigarettes or chewing tobacco or 
snuff (i.e., cigars, snuff, pipes, nicotine replacement therapy products or any product 
containing nicotine) during the past five days as well as 5318 participants who did not 
provide information on past five day tobacco use. We then categorized study participants 
into four mutually exclusive groups based on their reported cigarette and smokeless tobacco 
use: 1) “non-tobacco users” reported having smoked fewer than 100 cigarettes in their lives 
and not having used cigarettes, chewing tobacco, or snuff in the past five days, 2) 
“smokeless tobacco users” reported using chewing tobacco or snuff in the past five days and 
currently not using cigarettes at all (228 smokeless tobacco users who reported being former 
cigarette smokers, having smoked at least 100 cigarettes but currently not smoking at all, 
were excluded from the analysis for cadmium due to its long biologic half-life, which can be 
upwards of 10 years (21)), 3) “cigarette smokers” reported having smoked at least 100 
cigarettes in their lives and currently smoking every day or some days and not having used 
chewing tobacco of snuff in the past five days, and 4) “dual cigarette and smokeless tobacco 
users” reported having smoked at least 100 cigarettes in their lives, currently smoking every 
day or some days, and having used chewing tobacco or snuff in the past five days. We did 
not include former cigarette smokers who had not used chewing tobacco of snuff in the past 
five days in the analysis. The analysis included a total of 23,684 participants.
Biomarkers of Exposure
The biomarkers of exposure selected for this analysis were chosen due to their relevance to 
tobacco exposure and health outcomes. Cotinine is the primary proximate metabolite of 
nicotine (22, 23). NNAL is a metabolite of the TSNA 4-(methylnitrosamino)-1-(3-
pyridyl)-1-butanone (NNK), which has been identified as a known human carcinogen by the 
International Agency on Research on Cancer (24, 25). NNK itself is formed from the 
nitrosation of nicotine or the related alkaloid pseudooxynicotine (26). Lead, cadmium, 
mercury, and arsenic are elements known to have toxic effects that can be found in tobacco 
products as well as in other environmental sources (27-30). CYMA is a metabolite of 
acrylonitrile and a selective biomarker of exposure to smoke (31). Urinary arsenic 
concentrations were available for 2003-2012 NHANES participants, urinary NNAL 
concentrations were available for 2007-2012 NHANES participants, and urinary CYMA 
concentrations were available for 2005-2006 and 2011-2012 survey participants. Data for 
other biomarkers were available from 1999-2012.
The analytical methods used to obtain these data are available in NHANES documentation 
(20). Serum cotinine was measured by an isotope dilution - liquid chromatography / 
atmospheric pressure chemical ionization tandem mass spectrometry process. The half-life 
of cotinine is 15-20 hours, and its availability in blood, urine, and saliva makes it a 
commonly used biomarker of recent nicotine exposure (23, 32). Urinary total NNAL was 
measured using liquid chromatography linked to tandem mass spectrometry. The half-life of 
NNAL has been estimated to be 10–18 days (33). Blood cadmium, lead, and total mercury 
were measured using inductively coupled plasma mass spectrometry. Urinary total arsenic 
was measured using liquid chromatography coupled to plasma dynamic reaction cell mass 
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spectrometry. Urinary CYMA was measured using liquid chromotography coupled with 
electro spray tandem mass spectrometry. For concentrations below the limit of detection 
(LOD), a value equal to the LOD divided by the square root of two was used in analysis.
Demographic Variables
NHANES participants reported information on sex, age, race/ethnicity, and educational 
attainment. Race/ethnicity was subsequently categorized as non-Hispanic White, non-
Hispanic Black, Mexican-American, other Hispanic, and other race including multi-racial. 
Educational attainment was categorized as less than high school graduate or equivalent, high 
school graduate or equivalent, and more than high school graduate or equivalent. Body mass 
index (BMI) for survey participants was calculated as kg/m2 from their measured height and 
weight as a continuous variable.
Statistical Analysis
Demographic and tobacco use variables were characterized using means for continuous 
variables and percentages for categorical variables. Biomarker concentrations were log-
transformed for the analysis to minimize the effects of skewness in the data on estimates, 
and geometric means of observed biomarker concentrations by tobacco use category were 
calculated. Univariate and multivariate linear regression analysis were also used to analyze 
the relationship between biomarkers of exposure and tobacco use category, adjusting for sex, 
age, race/ethnicity, educational attainment, and BMI. Geometric mean ratios and 95% 
confidence intervals (CIs), from these analyses were calculated by exponentiating the 
estimated coefficients and their standard errors. Geometric mean biomarker concentrations 
were also calculated for cotinine and NNAL by two-year NHANES survey cycle and plotted 
by time. Box plots were also created to show the unweighted distribution of cotinine and 
NNAL concentrations for smokeless tobacco users who reported having used chewing 
tobacco or snuff on 1-2, 3-4, or 5 of the past days; the small number of NHANES 
participants who reported using both products in the past five days (n=4) were excluded 
from this particular analysis. All analyses were conducted using SAS version 9.3 (SAS 
Institute, Cary, NC), and all figures were constructed using R version 3.0.2 (R Core Team, 
Vienna, Austria). Analyses were conducted using the MEC sample weights with the 
exception of analyses for arsenic, which were conducted with environmental subsample 
weights, and analyses for CYMA, which were conducted with the 2005-2006 volatile 
organic compounds subsample weights and 2011-2102 smoking subsample weights. 
Analyses were conducted taking into account the complex survey design information on 
survey strata and primary sampling units provided by NCHS.
Results
Characteristics of the Study Population by Tobacco Use Status
Table 1 presents demographic and tobacco use information for the NHANES study 
participants according to tobacco use status. Of the 23,684 individuals, 488 were exclusive 
smokeless tobacco users, 6791 were exclusive cigarette smokers, 92 were dual cigarette and 
smokeless tobacco users, and 16,313 were non-tobacco users. Of the smokeless tobacco 
users, 309 individuals reported using chewing tobacco, 175 reported using snuff , and 4 
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reported using both chewing tobacco and snuff in the past five days (data not shown). 
Smokeless tobacco and dual users were overwhelmingly male, at 94.7% (95% CI = 92.1%, 
97.2%) and 99.4% (98.6%-100.0%) respectively. Dual users tended to be younger than 
members of other tobacco use groups with a mean age of 33.1 years (95% CI = 30.3, 35.8). 
Smokeless tobacco and dual users were also more likely to be non-Hispanic whites than 
members of other tobacco use groups at 88.7% (95% CI = 85.3%-92.1%) and 94.2% 
(90.1%-98.2%) respectively. The estimated mean number of cigarettes that dual users 
smoked on days that they smoked cigarettes in the past five days was less than the estimated 
mean for cigarette smokers, at 11.9 compared with 14.8 cigarettes, but the difference was not 
statistically significant (p = 0.071). There was a slight difference in the average number of 
days that cigarette smokers and dual users had smoked cigarettes in the past five days at 4.6 
and 4.2 days respectively (p = 0.042). Smokeless tobacco users tended to have consistently 
used smokeless tobacco in the past five days, with an average of 4.2 days (95% CI = 4.1-4.4) 
having used chewing tobacco for chewing tobacco users and an average of 4.3 days (95% CI 
= 4.1-4.5) having used snuff for snuff users.
Analysis of Biomarkers of Exposure by Tobacco Use Status
Table 2 presents geometric mean biomarker concentrations by tobacco use status. Mean 
serum cotinine concentrations were higher for smokeless tobacco users (178.9 ng/mL, 95% 
CI = 145.5, 220.0) than for cigarette smokers (130.6 ng/mL, 95% CI = 122.3, 139.6). 
Cotinine concentrations for dual users (184.1 ng/mL, 95% CI = 132.4, 256.0) were similar to 
concentrations for smokeless tobacco users. Mean urinary NNAL concentrations were 
higher for smokeless tobacco users (583.0 pg/mg creatinine, 95% CI = 445.2, 763.5) and 
dual users (430.3 pg/ mg creatinine, 95% CI = 284.8, 650.1) than for cigarette smokers 
(217.6 pg/mg creatinine, 95% CI = 193.0, 245.2). NNAL concentrations were also 
consistently higher for smokeless tobacco users compared with cigarette smokers when 
analyzed in terms of concentration categories. For example, 37.5% (95% CI = 28.6, 46.4%) 
of smokeless tobacco users had NNAL concentrations below 500 pg/mg creatinine and 
62.2% (95% CI = 54.6%, 69.7%) had concentrations below 1000 pg/mg creatinine. In 
contrast, 74.2% (95% CI = 70.4%, 78.1%) of smokers had NNAL concentrations below 500 
pg/mg creatinine and 94.1% (95% CI = 92.4%, 95.8%) had concentrations below 1000 
pg/mg creatinine. Mean NNAL concentrations were generally comparable for chewing 
tobacco (402.3 pg/mg creatinine, 95% CI = 294.3, 549.9) and snuff (463.7 pg/mg creatinine, 
95% CI = 315.6, 681.2) users. Exclusion of the relatively small proportion of current 
cigarette smokers who reported not having smoked cigarettes in the past five days (n=301 of 
6791) in sensitivity analysis produced similar results. For example, the geometric mean 
concentration of cotinine for the remaining smokers was 156.7 ng/mL (95% CI = 150.3, 
163.4) and the mean concentration for NNAL was 247.3 pg/mg creatinine (95% CI = 225.4, 
271.3).
Mean concentrations of blood lead were higher among smokeless tobacco users (1.76 μg/L, 
95% CI = 1.62, 1.91), dual users (1.76 μg/L, 95% CI = 1.55, 2.00), and cigarette smokers 
(1.76 μg/L, 95% CI = 1.71, 1.81) compared with non-tobacco users (1.18 μg/L, 95% CI = 
1.16, 1.21). Mean concentrations of blood cadmium, blood mercury, and urinary arsenic 
were not elevated among smokeless tobacco users compared with non-tobacco users.
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Mean CYMA concentrations were higher among cigarette smokers (117.3 ng/mg creatinine, 
95% CI = 103.1, 133.4) and dual users (35.4 ng/mg creatinine, 95% CI = 2.1, 606.8) but not 
among smokeless tobacco users (2.21 ng/mg creatinine, 95% CI = 1.11, 4.39) compared 
with non-tobacco users (1.47 ng/mg creatinine, 95% CI = 1.37, 1.58).
Associations between Biomarkers of Exposure and Tobacco Use Status
Table 3 presents results from multivariate regression analyses conducted to analyze whether 
tobacco use status was associated with higher biomarker concentrations, adjusting for 
demographic and socioeconomic factors.
After adjustment for age, sex, race/ethnicity, education, and BMI, smokeless tobacco users, 
cigarette smokers, and dual users had increased geometric mean ratios for serum cotinine 
compared with non-tobacco users. Smokeless tobacco users also had increased geometric 
mean ratios compared with cigarette smokers (p = 0.04). Smokeless tobacco users, cigarette 
smokers, and dual users also had increased geometric mean ratios for urinary NNAL 
compared with non-tobacco users, and smokeless tobacco users and dual users had increased 
geometric mean ratios compared with cigarette smokers.
Smokeless tobacco users, along with cigarette smokers and dual users, had increased 
geometric mean ratios for blood lead compared with non-tobacco users. Smokeless tobacco 
users did not have increased geometric mean ratios for any of the other biomarkers.
Trends in Tobacco-Specific Biomarkers Over Time
Figure 1 presents geometric mean serum cotinine and urinary NNAL concentrations for 
cigarette smokers and smokeless tobacco users over time. Cotinine concentrations for 
smokers and smokeless users were relatively consistent over time, although estimates for the 
smaller number of smokeless tobacco users showed more variability. Tests of trend for 
cotinine concentrations produced a p-value of 0.895 for smokers and 0.403 for smokeless 
tobacco users. Mean NNAL concentrations for smokers were relatively consistent from 
2007-2008 to 2011-2012 but declined dramatically for smokeless tobacco users from a 
geometric mean of 1013.7 pg/mg creatinine (95% CI = 738.9, 1390.8, n = 81) in 2007-2008 
to 328.6 pg/mg creatinine (95% CI = 164.7, 655.6, n = 53) in 2011-2012. Tests of trend for 
NNAL concentrations produced a p-value of 0.943 for smokers and 0.003 for smokeless 
tobacco users.
Analysis of Dose-Response Relationship for Tobacco-Specific Biomarkers
Figure 2 presents boxplots showing the distribution of cotinine and NNAL concentrations 
for chewing tobacco and snuff users by frequency of use in terms of the number of days that 
they had used the product in the past five days. The figure shows that concentrations 
consistently increased with number of days of use. Tests of trend for the association between 
biomarker concentrations and days using the product produced p-values less than 0.0001 for 
chewing tobacco and snuff for cotinine and equal to 0.003 for chewing tobacco and 0.03 for 
snuff for NNAL.
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We have analyzed biomarkers of tobacco exposure – serum cotinine, urinary total NNAL, 
blood cadmium, blood lead, blood total mercury, urinary arsenic, and urinary CYMA, from 
over 23,000 NHANES participants from 1999-2012. To our knowledge, this work provides 
the first estimates from a large, nationally representative US health survey population that 
compare serum cotinine and urinary NNAL concentrations for smokeless tobacco users with 
those of cigarette smokers and present trends in urinary NNAL concentrations over time. We 
have found higher cotinine concentrations and much higher NNAL concentrations for 
smokeless tobacco users compared with cigarette smokers as well as higher NNAL 
concentrations for dual users compared with smokers. We have also found evidence that 
NNAL concentrations among smokeless tobacco users are declining over time, although the 
sample sizesfor this analysis were limited due to the introduction of analysis of NNAL with 
the 2007-2008 NHANES cycle. We also found that smokeless tobacco users have higher 
concentrations of blood lead, but not blood cadmium, blood mercury, urinary arsenic, or 
urinary CYMA, compared with non-tobacco users.
The results for NNAL in this study are rather striking, both in terms of the magnitude of 
overall exposure for smokeless tobacco users as well as the apparent decrease in NNAL 
exposure over time. Our results confirm with a large and nationally representative survey 
sample previous findings that NNAL and cotinine concentrations were as high as or higher 
among smokeless tobacco users as among cigarette smokers (15). Relative concentrations 
for NNAL were particularly high, with concentrations for smokeless tobacco users being on 
average almost three times as high as concentrations for cigarette smokers. The causes of 
these differences in exposure between cigarette and smokeless tobacco users are not entirely 
understood. It has been previously suggested that higher urinary cotinine concentrations for 
smokeless tobacco users could be related to first pass clearance of swallowed tobacco juice, 
whereby constituents could to some extent be metabolized and excreted before they reach 
the systemic circulatory system (15). Similar issues related to metabolism and clearance of 
NNK and NNAL could also affect urinary NNAL levels among smokeless tobacco users in 
this study. Even so, results from this and previous research (15) suggest that nicotine and 
NNK exposure in smokeless tobacco users is at least as high as, if not higher than, exposure 
among cigarette smokers.
Although based on limited sample sizes, estimated NNAL concentrations for smokeless 
users fell by more than two thirds from 2007-2008 to 2011-2012, even though cotinine 
concentrations for these users were relatively unchanged during this period. The decrease in 
NNAL concentrations among smokeless tobacco users could be the result of a variety of 
factors including reductions in the quantity of smokeless tobacco used, although estimates 
from these NHANES do not show a decrease in the number of days that individuals used 
chewing tobacco or snuff in the past five days. For example, chewing tobacco users reported 
using the product on an average of 4.5 days (95% CI = 4.4, 4.7) in 2007-2008 and 4.3 days 
(95% CI = 3.7, 4.9) in 2011-2012. Moreover, cotinine concentrations among smokeless 
tobacco users were relatively consistent during the period. The decrease in NNAL 
concentrations could result in part from reductions in TSNAs in smokeless tobacco products 
generally. Borgerding et al. (34) analyzed toxicant concentrations in 43 US smokeless 
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tobacco products sold in the US in 2006 and 2007 and found that TSNA concentrations 
observed for all of these commercial products were lower than historically reported values. 
Fisher et al. (10) found a decrease in average TSNAs for three commercial moist snuff 
products from 1997 to 2010, particularly in the period prior to 2005. The decrease in NNAL 
concentrations among smokeless tobacco users may also reflect a movement among users to 
smokeless products with lower levels of certain harmful constituents. Stepanov et al. (12), 
for example, analyzed total TSNAs in relatively new smokeless tobacco products such as 
Taboka, Marlboro Snus, Camel Snus, and Skoal Dry as compared with popular traditional 
brands of moist snuff such as Copenhagen Snuff, Skoal Lung Cut, and Kodiak Wintergreen 
that were purchased in 2006-2007. They found that total TSNAs averaged 1.97 μg/g dry 
weight tobacco in Taboka, Marlboro Snus, and Camel Snus, 4.54 μg/g dry weight tobacco in 
Skoal Dry, and 7.42 μg/g in the traditional moist snuff brands. Similar results were found 
specifically for NNK, the precursor of NNAL. These researchers subsequently analyzed 
novel smokeless tobacco products in 2010 (35) and 2011 (36) and found that TSNA levels in 
products such as Marlboro and Camel snus increased and decreased over time. Changes 
have also been observed in smokeless tobacco product use over time. Delnevo et al. (37) 
analyzed smokeless tobacco convenience store sales data from 2005 to 2011 and found 
changes in product market share durng this period. Market share for chewing tobacco, for 
example, decreased from 9.0% to 4.3% durng this time, and sales of snus increased from 
0.0% to 3.7%. Approximately 90% of smokeless tobacco sold in convenience stores 
throughout the period was moist snuff, but the market share of portion pouches within this 
category increased from 5.5% to 14.5% during the period. Trends in NNAL concentrations 
among smokeless tobacco users should continue to be monitored and evaluated over time.
This analysis has also found that blood lead levels in smokeless tobacco users are 
comparable to those of cigarette smokers and higher than levels for non-tobacco users. This 
result is consistent with previous analysis of NHANES data (17). Further research on this 
topic is needed to establish that smokeless tobacco is the cause of these elevated lead levels 
among users and, if so, to identify the elements of smokeless tobacco production that 
contribute to these higher levels. CYMA concentrations were also higher among cigarette 
smokers and dual cigarette and smokeless tobacco users, but not among exclusive smokeless 
tobacco users, compared with non-tobacco users. This result is consistent with expectations, 
given that CYMA is a biomarker for smoke exposure.
Results in this study are subject to certain limitations, primarily due to the nature of the data 
being collected. First, we do not have detailed information on the type of smokeless tobacco 
product used, such as information on brand or product type such as snus, apart from chewing 
tobacco and snuff. Second, we do not have information on the quantity of product used, such 
as amount used per day, apart from the number of days using the product in the past five 
days. Finally, NHANES participants were only asked about past five day use of certain 
tobacco products other than cigarettes. We were thus unable to evaluate any effects of 
duration or former use of smokeless tobacco products. We also have no information on e-
cigarette use in NHANES data, but e-cigarette use was minimal during much of the period 
of this analysis.
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Our results have shown that smokeless tobacco use is significantly associated with high 
levels of exposure to known harmful and addictive constituents, in some cases greater than 
observed among cigarette smokers. This exposure is a cause of considerable concern for 
individual and public health. These findings also demonstrate the need for continuing study 
and surveillance of the toxic constituents of smokeless tobacco as well as their health effects 
on the individuals who use them.
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Table 1
Characteristics of National Health and Nutrition Examination Survey (NHANES) Participants by Tobacco Use 
Status: United States 1999-2012
Characteristics N Non-Tobacco Users Exclusive Smokeless 
tobacco users
Exclusive Cigarette Smokers Dual Cigarette and 
Smokeless Tobacco 
Users
(N=16313) (N=488) (N=6791) (N=92)
Age 23684
45.9 (45.3, 46.5)
* 44.2 (42.7, 45.7) 42.0 (41.5, 42.4) 33.1 (30.3, 35.8)
Sex
    Male 10571 40.1% (39.2%-41.0%) 94.7% (92.1%-97.2%) 53.9% (52.5%-55.4%) 99.4% (98.6%-100.0%)
    Female 13113 59.9% (59.0%-60.8%) 5.3% (2.8%-7.9%) 46.1% (44.6%-47.5%) 0.6% (0.0%-1.4%)
Race/Ethnicity
    Mexican -American 4583 9.0% (7.6%-10.3%) 2.5% (1.3%-3.7%) 6.8% (5.6%-8.0%) 2.1% (0.0%-4.2%)
    Other Hispanic 1765 5.9% (4.7%-7.2%) 0.7% (0.0%-1.5%) 4.9% (3.4%-6.4%) 1.4% (0.0%-4.3%)
    Non-Hispanic White 10780 66.8% (64.2%-69.4%) 88.7% (85.3%-92.1%) 70.8%(67.90%-73.7%) 94.2% (90.1%-98.2%)
    Non-Hispanic Black 5095 11.7% (10.3%-13.2%) 5.7% (3.5%-7.8%) 12.3% (10.7%-13.9%) 1.1% (0.0%-2.4%)
    Other 1461 6.6% (5.7%-7.4%) 2.5% (0.9%-4.1%) 5.1% (4.2%-6.0%) 1.2% (0.0%-3.3%)
Education
    < High School 
Graduate
6936 15.4% (14.4%-16.4%) 20.3% (15.9%-24.6%) 27.7% (26.1%-29.3%) 15.1% (7.6%-22.6%)
    High School Graduate 5587 21.1% (20.1%-22.2%) 34.2% (28.8%-39.7%) 31.5% (30.0%-32.9%) 42.7% (30.0%-55.4%)
    > High School 
Graduate
11134 63.5% (62.0%-65.0%) 45.5% (40.0%-51.0%) 40.9% (39.0%-42.8%) 42.3% (30.6%-54.0%)
Body Mass Index 
(BMI), kg/m2
23311 28.7 (28.5, 28.8) 30.0 (29.3, 30.8) 27.5 (27.3, 27.6) 26.7 (25.5, 27.9)
Past Five Day 
Cigarette/Smokeless 
Tobacco Use
    # of Days Smoked 
Cigarettes
4.6 (4.6, 4.6) 4.2 (3.9, 5.6)
    # of Cigarettes 
Smoked per Day on 
Days Smoking 
Cigarettes
14.8 (14.4, 15.3) 11.9 (8.6, 15.2)
    # of Days Used 
Chewing Tobacco
4.2 (4.1-4.4) 3.7 (3.3-4.2)
    # of Days Used Snuff 4.3 (4.1-4.5) 3.5 (3.0, 4.0)
Note: Non-tobacco users reported not having smoked at least 100 cigarettes in their lives and not having used cigarettes, chewing tobacco, or snuff 
in the past five days.
Smokeless tobacco users reported having used chewing tobacco or snuff in the past five days and currently not smoking cigarettes at all.
Cigarette smokers reported having smoked at least 100 cigarettes in their lives and currently smoking every day or some days and not having used 
chewing tobacco of snuff in the past five days.
Dual cigarette and smokeless tobacco users reported having smoked at least 100 cigarettes in their lives, currently smoking every day or some days, 
and having used chewing tobacco or snuff in the past five days
Survey participants were excluded from each group if they reported having used pipes, cigars, or nicotine gum, patches, or other nicotine products 
in the past five days
*
95% confidence intervals for means and percentages are shown in parentheses.
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Table 3
Geometric Mean Ratios for Biomarkers of Exposure by Tobacco Use Status, NHANES 1999-2012
Biomarker Tobacco Use Category Unadjusted Geometric Mean Ratio 
(95% Cl)
Adjusted Geometric Mean Ratio 
(95% Cl)
Serum cotinine Exclusive smokeless tobacco users 4160 (3406, 5081) 3194 (2623, 3888)
Exclusive cigarette smokers 3027 (2801, 3270) 2439 (2240, 2655)
Dual cigarette/smokeless tobacco users 4265 (3064, 5936) 3009 (2174, 4164)
Non-tobacco users (Ref) 1 1
Urinary NNAL Excluisve smokeless tobacco users 760 (574, 1006) 587 (451, 764)
Exclusive cigarette smokers 229 (205, 255) 190 (171, 210)
Dual cigarette/smokeless tobacco users 541 (313, 935) 393 (252, 614)
Non-tobacco users (Ref) 1 1
Blood cadmium Exclusive smokeless tobacco users 0.82 (0.75, 0.90) 1.00 (0.93, 1.08)
Exclusive cigarette smokers 3.52 (3.41, 3.63) 3.69 (3.57, 3.81)
Dual cigarette/smokeless tobacco users 2.41 (1.93, 3.00) 3.10 (2.50, 3.85)
Non-tobacco users (Ref) 1 1
Blood lead Exclusive smokeless tobacco users 1.49 (1.37, 1.61) 1.30 (1.21, 1.38)
Exclusive cigarette smokers 1.48 (1.44, 1.53) 1.46 (1.42, 1.49)
Dual cigarette/smokeless tobacco users 1.49 (1.31, 1.70) 1.50 (1.34, 1.67)
Non-tobacco users (Ref) 1 1
Blood mercury Exclusive smokeless tobacco users 0.81 (0.71, 0.92) 0.86 (0.75, 0.98)
Exclusive cigarette smokers 0.76 (0.72, 0.80) 0.83 (0.79, 0.87)
Dual cigarette/smokeless tobacco users 0.62 (0.48, 0.79) 0.70 (0.55, 0.89)
Non-tobacco users (Ref) 1 1
Urinary arsenic Exclusive smokeless tobacco users 0.91 (0.75, 1.09) 0.86 (0.73, 1.02)
Exclusive cigarette only smokers 0.83 (0.76, 0.92) 0.87 (0.80, 0.94)
Dual cigarette/smokeless tobacco users 0.83 (0.45, 1.55) 0.81 (0.59, 1.10)
Non-tobacco users (Ref) 1 1
Urinary CYMA Exclusive smokeless tobacco users 2.04 (1.04, 4.01) 1.62 (0.83, 3.18)
Exclusive cigarette only smokers 84.9 (72.5, 99.3) 75.3 (65.2, 87.1)
Dual cigarette/cigarette smokers 33.5 (0.8, 1398.5) 18.4 (0.7, 463.5)
Non-tobacco users (Ref) 1 1
Note: NNAL data were available for 2007-2012 NHANES participants, arsenic data were available for 2003-2012 NHANES participants, and 
CYMA data were available for 2005-2006 and 2011-2012 NHANES participants. The adjusted geometric mean ratios control for age, sex, race/
ethnicity, educational attainment, and body mass index For urinary arsenic, CYMA, and NNAL, the adjusted ratios further control for urinary 
creatinine.
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